-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network News, March 25.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
Secondary hyperparathyroidism.
Secondary hyperparathyroidism.
Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
According to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
According to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
Source: Mi Nei Net database
Medical Network News, March 25.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
Secondary hyperparathyroidism.
Secondary hyperparathyroidism.
Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
According to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
According to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
Source: Mi Nei Net database
Medical Network News, March 25.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Recently, Jiangsu Osaikang Pharmaceutical entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.
According to data from Menet.
com, in the first half of 2020, the sales of terminal Paricalcitol injections in public medical institutions in China increased by more than 300% year-on-year.
Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.
Secondary hyperparathyroidism.
Secondary hyperparathyroidism.
Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.
According to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
Hospital Hospital Hospital Medicine Medicine MedicineAccording to data from Menet.
com, in 2019, although the sales of terminal paricalcitol injections in China's urban public hospitals , county-level public hospitals, urban community centers, and township health centers (referred to as Chinese public medical institutions) are less than 100 million yuan, its growth rate is Astonishing, the year-on-year growth in the first half of 2020 will exceed 300%.
Among them, Hengrui Medicine has the largest market share, exceeding 80%.
Source: MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
At present, Paricalcitol injection has been approved by Jiangsu Hengrui Pharmaceutical, Shanxi Weiqida Bright Pharmaceutical, Chengdu Yuandong Biopharmaceutical, and Beijing Tide Pharmaceutical.
Jiangsu Aosaikang Pharmaceutical and Suzhou Netac Biotech|Hebei Kaiwei Pharmaceutical reported production of 6 types of imitations and 4 types of imitations respectively.
Source: Mi Nei Net database
